Consolidated Sep 2026 vs Sep 2025: revenue Rs266 crore vs 144; profit Rs18.6 crore vs Rs9.4 crore
FREDUN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended 30 Sep 2026: revenue Rs265.85 crore, up 85% year on year from Rs143.59 crore; profit after tax Rs18.57 crore, up 97% from Rs9.43 crore. Consolidated half year to Sep 2026: revenue Rs493.61 crore; profit after tax Rs31.71 crore. Standalone quarterly profit after tax was Rs18.83 crore. Board approved an NSE listing application, subject to approvals. Auditor review was unmodified; prior figures were regrouped or restated.
Strong revenue and profit growth may support the share price, while an NSE listing could widen investor access after approvals.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.